Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 18/20 | 0.42 |
| ▸ | MC5R | P33032 | 17/20 | 0.42 |
| ▸ | MC3R | P41968 | 13/20 | 0.42 |
| ▸ | MC1R | Q01726 | 8/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1309107 | 1.00 | MC4R (0.42) | MC4RMC5RMC3RMC1RHTT | |
| SCHEMBL1325076 | 0.96 | MC4R (0.41) | MC4RMC5RMC3RMC1RHTT | |
| SCHEMBL1325077 | 0.96 | MC4R (0.41) | MC4RMC5RMC3RMC1RHTT | |
| SCHEMBL2315290 | 0.93 | MC4R (0.43) | MC4RMC5RMC3RMC1RHTT | |
| SCHEMBL1307815 | 0.93 | MC4R (0.43) | MC4RMC5RMC3RMC1RHTT | |
| SCHEMBL1307814 | 0.93 | MC4R (0.43) | MC4RMC5RMC3RMC1RHTT | |
| SCHEMBL1310141 | 0.93 | MC4R (0.43) | MC4RMC5RMC3RMC1RHTT | |
| SCHEMBL2316504 | 0.93 | MC4R (0.37) | MC4RMC5RMC3RMC1RHTT | |
| SCHEMBL1309282 | 0.93 | MC4R (0.50) | MC4RMC5RMC3RMC1R | |
| SCHEMBL1309284 | 0.93 | MC4R (0.50) | MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2790692-B1 | ASSOCIATION OF A PROSTAGLANDIN RECEPTOR AGONIST AND OF A MC1R RECEPTOR AGONIST FOR TREATING AND/OR PREVENTING PIGMENTATION DISORDERS | GALDERMA RES & DEV (FR) | 2016-11-23 | — | — | EP | claimed |
| US-9364455-B2 | Combination of a prostaglandin receptor agonist and an MC1R receptor agonist for the treatment and/or prevention of pigmentation disorders | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-14 | — | — | US | claimed |
| US-20140371147-A1 | COMBINATION OF A PROSTAGLANDIN RECEPTOR AGONIST AND AN MC1R RECEPTOR AGONIST FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-12-18 | — | — | US | claimed |
| US-8877968-B2 | Melanocortin receptor modulators, process for preparing them and use there in human medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-11-04 | — | — | US | claimed |
| EP-2352728-B1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RES & DEV (FR) | 2014-05-21 | — | — | EP | claimed |
| US-20110275657-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-10 | — | — | US | claimed |
| US-9364455-B2 | Combination of a prostaglandin receptor agonist and an MC1R receptor agonist for the treatment and/or prevention of pigmentation disorders | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-14 | — | — | US | disclosed |
| US-20140371147-A1 | COMBINATION OF A PROSTAGLANDIN RECEPTOR AGONIST AND AN MC1R RECEPTOR AGONIST FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-12-18 | — | — | US | disclosed |
| US-8877968-B2 | Melanocortin receptor modulators, process for preparing them and use there in human medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-11-04 | — | — | US | disclosed |
| EP-2352728-B1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RES & DEV (FR) | 2014-05-21 | — | — | EP | disclosed |
| US-20110275657-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-10 | — | — | US | disclosed |
| EP-2352728-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | Galderma Research & Development (FR) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010052255-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371147-A1 | COMBINATION OF A PROSTAGLANDIN RECEPTOR AGONIST AND AN MC1R RECEPTOR AGONIST FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS | MC1R, MC3R, MC5R | MC4R 7/4885MC5R 3/4885MC3R 2/4885 |
| US-20110275657-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS | MC1R, MC5R, MC3R | MC4R 4/4885MC5R 2/4885MC3R 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.